Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Asahi Kasei Pharma Corporation, Shizuoka, Japan.
Sci Signal. 2021 Jun 15;14(687):eaba0717. doi: 10.1126/scisignal.aba0717.
Expression of the transmembrane protein Tim-3 is increased on dysregulated T cells undergoing chronic activation, including during chronic infection and in solid tumors. Thus, Tim-3 is generally thought of as an inhibitory protein. We and others previously reported that under some circumstances, Tim-3 exerts paradoxical costimulatory activity in T cells (and other cells), including enhancement of the phosphorylation of ribosomal S6 protein. Here, we examined the upstream signaling pathways that control Tim-3-mediated increases in phosphorylated S6 in T cells. We also defined the localization of Tim-3 relative to the T cell immune synapse and its effects on downstream signaling. Recruitment of Tim-3 to the immune synapse was mediated exclusively by the transmembrane domain, replacement of which impaired the ability of Tim-3 to costimulate T cell receptor (TCR)-dependent S6 phosphorylation. Furthermore, enforced localization of the Tim-3 cytoplasmic domain to the immune synapse in a chimeric antigen receptor still enabled T cell activation. Together, our findings are consistent with a model whereby Tim-3 enhances TCR-proximal signaling under acute conditions.
跨膜蛋白 Tim-3 的表达在经历慢性激活的失调 T 细胞中增加,包括在慢性感染和实体瘤中。因此,Tim-3 通常被认为是一种抑制蛋白。我们和其他人之前曾报道过,在某些情况下,Tim-3 在 T 细胞(和其他细胞)中发挥矛盾的共刺激活性,包括增强核糖体 S6 蛋白的磷酸化。在这里,我们研究了控制 Tim-3 介导的 T 细胞中磷酸化 S6 增加的上游信号通路。我们还定义了 Tim-3 相对于 T 细胞免疫突触的定位及其对下游信号的影响。Tim-3 向免疫突触的募集完全由跨膜结构域介导,该结构域的替换损害了 Tim-3 刺激 TCR 依赖性 S6 磷酸化的能力。此外,在嵌合抗原受体中将 Tim-3 的细胞质结构域强制定位到免疫突触仍然能够激活 T 细胞。总之,我们的研究结果与一种模型一致,即在急性条件下,Tim-3 增强 TCR 近端信号。
Mol Cell Biol. 2011-8-1
Proc Natl Acad Sci U S A. 2018-2-20
J Exp Med. 2015-12-14
F1000Res. 2012-8-10
Proc Natl Acad Sci U S A. 2005-11-22
Nat Cell Biol. 2025-5
Eur J Med Res. 2024-12-18
Int J Biol Sci. 2024-11-4
Front Immunol. 2024
Signal Transduct Target Ther. 2024-5-22
Onco Targets Ther. 2018-10-16
Int Immunopharmacol. 2018-7-2
N Engl J Med. 2018-7-5
Nat Rev Immunol. 2018-8
Science. 2018-3-23
F1000Res. 2018-3-14